Amneal Pharmaceuticals Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Amneal Pharmaceuticals (NYSE:AMRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Volatility and Risk

Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Amneal Pharmaceuticals, as reported by MarketBeat.com.

Arrowhead Pharmaceuticals currently has a consensus price target of $85.3077, suggesting a potential upside of 26.10%. Amneal Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Arrowhead Pharmaceuticals and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Arrowhead Pharmaceuticals and Amneal Pharmaceuticals' gross revenue, earnings per share and valuation.

Arrowhead Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amneal Pharmaceuticals beats Arrowhead Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Amneal Pharmaceuticals (NYSE:AMRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Insider and Institutional Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by company insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for GW Pharmaceuticals and Amneal Pharmaceuticals, as reported by MarketBeat.com.

GW Pharmaceuticals currently has a consensus price target of $204.0909, suggesting a potential downside of 6.77%. Amneal Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than GW Pharmaceuticals.

Volatility and Risk

GW Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Valuation & Earnings

This table compares GW Pharmaceuticals and Amneal Pharmaceuticals' gross revenue, earnings per share and valuation.

GW Pharmaceuticals has higher earnings, but lower revenue than Amneal Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GW Pharmaceuticals and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats GW Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Amneal Pharmaceuticals and Ascendis Pharma A/S, as reported by MarketBeat.

Amneal Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 53.89%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Ascendis Pharma A/S's gross revenue, earnings per share and valuation.

Ascendis Pharma A/S has lower revenue, but higher earnings than Amneal Pharmaceuticals. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Amneal Pharmaceuticals and TG Therapeutics, as reported by MarketBeat.

Amneal Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 18.85%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.92%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and TG Therapeutics' gross revenue, earnings per share and valuation.

TG Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. TG Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and TG Therapeutics' net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Amneal Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.

Amneal Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 42.00%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Ionis Pharmaceuticals' gross revenue, earnings per share and valuation.

Ionis Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Ionis Pharmaceuticals beats Amneal Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Amneal Pharmaceuticals and Sarepta Therapeutics, as reported by MarketBeat.

Amneal Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 18.85%. Sarepta Therapeutics has a consensus price target of $150.4762, suggesting a potential upside of 109.58%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Sarepta Therapeutics' gross revenue, earnings per share and valuation.

Amneal Pharmaceuticals has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and Sarepta Therapeutics' net margins, return on equity and return on assets.

Summary

Amneal Pharmaceuticals beats Sarepta Therapeutics on 9 of the 14 factors compared between the two stocks.